(Q39181189)

9 September 2017

IL-28B (IFN-λ3) and IFN-α synergistically inhibit HCV replication (English)

1 reference

9 September 2017

14

1 reference

9 September 2017

H Shindo

1

1 reference

9 September 2017

S Maekawa

2

1 reference

9 September 2017

K Komase

3

1 reference

9 September 2017

M Miura

4

1 reference

9 September 2017

M Kadokura

5

1 reference

9 September 2017

R Sueki

6

1 reference

9 September 2017

N Komatsu

7

1 reference

9 September 2017

K Shindo

8

1 reference

9 September 2017

F Amemiya

9

1 reference

9 September 2017

Y Nakayama

10

1 reference

9 September 2017

T Inoue

11

1 reference

9 September 2017

M Sakamoto

12

1 reference

9 September 2017

A Yamashita

13

1 reference

9 September 2017

N Enomoto

15

1 reference

9 September 2017

7 August 2012

1 reference

Journal of Viral Hepatitis

9 September 2017

1 reference

9 September 2017

20

1 reference

9 September 2017

4

1 reference

9 September 2017

281-289

1 reference

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

9 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01649.X

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01649.X

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01649.X

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01649.X

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01649.X

Human interferon-lambda3 is a potent member of the type III interferon family.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01649.X

IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01649.X

Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01649.X

Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01649.X

Interleukin-29 functions cooperatively with interferon to induce antiviral gene expression and inhibit hepatitis C virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01649.X

Efficient replication of a full-length hepatitis C virus genome, strain O, in cell culture, and development of a luciferase reporter system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01649.X

IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01649.X

Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01649.X

Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01649.X

Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01649.X

IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01649.X

Interferon-β and interferon-λ signaling is not affected by interferon-induced refractoriness to interferon-α in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01649.X

USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon α response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01649.X

Interferon-lambda serum levels in hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01649.X

IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01649.X

IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01649.X

10.1111/J.1365-2893.2012.01649.X

21 January 2018

Identifiers

DOI

1 reference

9 September 2017

1 reference